Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...
INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial ...
Demonstrated a favorable safety and tolerability profile for VG-3927 across all cohorts, including elderly participants, with no serious adverse events reported. Achieved robust and dose-dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback